Neurogenic Detrusor Overactivity Global Market Report 2025

The neurogenic detrusor overactivity market size has grown strongly in recent years. It will grow from $1.69 billion in 2024 to $1.82 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The historic growth is attributed to a rise in neurological disorders, increased awareness among healthcare providers, broader adoption of pharmaceutical treatments, development of hospital and clinic facilities, and higher diagnosis rates.

The neurogenic detrusor overactivity market size is expected to see strong growth in the next few years. It will grow to $2.45 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. Growth drivers for the forecast period include the aging population, rising cases of spinal cord injuries, increased healthcare spending, advancements in minimally invasive therapies, and enhanced patient awareness and education. Key trends during this period include technological progress in stem cell therapies, innovation in drug delivery systems, improvements in neuromodulation devices, advances in personalized medicine research, and the development of less invasive treatment procedures.

The rising incidence of neurological disorders is expected to drive the growth of the neurogenic detrusor overactivity (NDO) market in the coming years. Neurological disorders are medical conditions that affect the brain, spinal cord, or nerves, resulting in issues with movement, sensation, cognition, or other bodily functions. As people live longer, the likelihood of age-related brain degeneration increases, contributing to the growing prevalence of these conditions. NDO is a form of bladder dysfunction often linked to neurological disorders such as spinal cord injury, multiple sclerosis, and Parkinson’s disease. These conditions interfere with normal nerve communication between the brain and bladder, leading to involuntary bladder contractions. For example, in April 2024, a study published by the American Academy of Neurology (AAN) indicated that there will be an estimated 4.9 billion cases of brain disorders globally by 2050, marking a 22% increase from around 4 billion cases in 2021. Consequently, the increasing number of neurological disorders is contributing to the expansion of the NDO market.

Major companies involved in the treatment of neurogenic detrusor overactivity are emphasizing the development of advanced generic therapies, such as beta-3 adrenergic receptor agonists, to provide effective bladder control solutions at lower costs. These drugs, such as mirabegron, help relax the detrusor muscle in the bladder, thereby enhancing bladder capacity and reducing symptoms like urgency and incontinence. For instance, in April 2024, Lupin Ltd., an Indian pharmaceutical company, received approval from the U.S. Food and Drug Administration (USFDA) to launch Mirabegron, a generic version of Myrbetriq, in the United States. As a once-daily oral treatment, Mirabegron provides a convenient and efficient option for managing overactive bladder (OAB) and neurogenic detrusor overactivity in pediatric patients. This approval underscores Lupin’s commitment to offering high-quality and affordable generic medications in key therapeutic areas.

In November 2024, Boston Scientific Corporation, a U.S.-based medical device company, acquired Axonics, Inc. to strengthen its portfolio in neuromodulation and urology. This acquisition aims to enhance Boston Scientific’s capabilities in treating overactive bladder and other urinary and bowel dysfunctions by incorporating Axonics' innovative sacral neuromodulation technologies. The integration of Axonics’ solutions will allow Boston Scientific to offer more comprehensive care options for pelvic health conditions. Axonics, Inc. is a U.S.-based medical technology firm that specializes in sacral neuromodulation systems designed to improve bladder control.

Major players in the neurogenic detrusor overactivity market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi S. A., Medtronic plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries, Apotex Inc., Viatris Inc., Sumitomo Pharma America Inc., Galderma, Ipsen, Coloplast A/S, Aurobindo Pharma Limited, Hisamitsu Pharmaceutical Co. Inc., Kaken Pharmaceutical Co. Ltd., and Hugel Inc.

North America was the largest region in the neurogenic detrusor overactivity market in 2024. The regions covered in neurogenic detrusor overactivity report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neurogenic detrusor overactivity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Neurogenic detrusor overactivity (NDO) is a bladder dysfunction that results from neurological conditions interfering with normal nerve signals between the brain, spinal cord, and the bladder's detrusor muscle. This disruption causes increased or involuntary contractions of the detrusor muscle, leading to symptoms such as urinary urgency, frequent urination, urge incontinence, and occasionally incomplete bladder emptying.

The primary treatment options for neurogenic detrusor overactivity (NDO) include non-surgical treatments, surgical interventions, and follow-up care. Non-surgical treatments involve medical management or therapies that address the condition without requiring invasive surgical procedures. These treatments are utilized across different patient groups, including both adults and children, and are delivered in various settings such as hospitals, urology clinics, rehabilitation centers, private practices, and long-term care facilities.

The neurogenic detrusor overactivity market research report is one of a series of new reports that provides neurogenic detrusor overactivity market statistics, including the neurogenic detrusor overactivity industry global market size, regional shares, competitors with the neurogenic detrusor overactivity market share, detailed neurogenic detrusor overactivity market segments, market trends, and opportunities, and any further data you may need to thrive in the neurogenic detrusor overactivity industry. These neurogenic detrusor overactivity market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurogenic detrusor overactivity market includes revenues earned by entities by providing services such as medication management, behavioral and lifestyle interventions, physiotherapy, absorbent products and skin care, and catheterization. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.